Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin AUD

    99,602.17
    +2,551.83 (+2.63%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

The global blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%

ReportLinker
·3-min read

during the forecast period. Growth in this market is mainly driven by the growing number of blood donations across the world, the rising prevalence of infectious diseases, and the rising demand for donated blood.

New York, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Blood Screening Market by Technology, Product & End User - Global Forecast to 2026" - https://www.reportlinker.com/p04603857/?utm_source=GNW


"The reagents & kits segment accounted for the highest growth rate in the blood screening market, by product & service, during the forecast period."
The blood screening market is segmented into reagents & kits, instruments, and software & services based on product.In 2020, the reagents & kits segment accounted for the highest growth rate in the blood screening market.

Market growth can largely be attributed to rising number of blood transfusions and blood donations. In addition, technological advancements in blood screening technologies and the increasing number of surgeries are stimulating the growth of this segment.
"Blood banks segment accounted for the highest CAGR."
Based on end users, the blood screening market is segmented into blood banks and hospitals.In 2020, the blood banks segment accounted for the highest growth rate.

This can be attributed to the growing number of organ transplantation surgeries, and rising awareness about blood safety.
"Asia Pacific: The fastest-growing region blood screening market."
The global blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.The Asia Pacific region is projected to register the highest CAGR during the forecast period.

Factors such as the increasing healthcare spending, increasing government efforts to increase awareness about early disease detection, growing per capita income, expansion of private-sector hospitals to rural areas in various APAC countries, the rising geriatric population in several APAC countries (coupled with the increasing prevalence of chronic disorders), and the presence of high-growth markets in the region. The low labor costs and the favorable regulatory environment in this region are also expected to propel market growth.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6% , and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
• Grifols (Spain)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott Laboratories, Inc. (US), bioMérieux (France)
• Bio-Rad Laboratories, Inc. (US)
• Becton, Dickinson and Company (US)
• Beckman Coulter, Inc. (Danaher) (US)
• DiaSorin (Italy)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific, Inc. (US)
• Ortho Clinical Diagnostics Inc. (US)
• GE Healthcare (US)
• Merck KGaA (Germany)
• PerkinElmer (US)
• Bio-Techne Corporation (US)
• GFE (Germany)
• Trinity Biotech (Ireland)
• Mindray (China)
• Maccura Biotechnology Co., Ltd. (China)
• Immucor, Inc. (US)
• Cellabs (Australia)
• Abnova Corporation (Taiwan)
• Enzo Biochem, Inc. (US)
• Cepheid (US).

Research Coverage:
This report provides a detailed picture of the global blood screening market.It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall blood screening market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Read the full report: https://www.reportlinker.com/p04603857/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001